Saturday 17 October 2026
Export VERU’s income statement to Excel — free account
Veru Inc.
VERU Healthcare Biotechnology
In the quarter to June 2026, EPS grew 40.0% and free cash flow was flat, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for three; insiders bought in the last twelve months.
2.30
0.14
−5.74%
Follow VERU
| Sep '25 | Sep '24 | Sep '23 | Sep '22 | Sep '21 | Sep '20 | Sep '19 | Sep '18 | Sep '17 | Sep '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | 5 | 2 | 2 | 5 | 5 | 5 | 3 | 3 | — |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 65.62 | 0.00 | 0.00 | 0.00 | 0.00 | 108.73 |
Altman Z-Score |
— | (5.84) | (11.71) | 7.68 | 15.96 | 2.64 | 2.28 | (0.42) | 6.98 | 4.70 |
P/S ratio |
— | 4.17 | 3.81 | 23.45 | 10.62 | 4.11 | 4.30 | 4.45 | 5.76 | 1.58 |
Altman Z″-Score (non-manufacturers) |
— | (16.17) | (27.98) | (3.27) | 10.19 | (4.52) | (3.14) | (5.50) | 4.91 | 7.99 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 92.57 | 0.00 |
P/Operating CF |
— | (23.79) | (6.53) | (44.21) | (806.81) | (512.73) | (143.22) | (25.07) | 136.18 | (42.51) |
Beneish M-Score |
— | (3.38) | (1.07) | (5.21) | (1.28) | (4.02) | (2.54) | (4.40) | (3.91) | (2.20) |
P/B ratio |
— | 3.21 | 3.15 | 11.15 | 4.27 | 5.81 | 4.23 | 2.39 | 1.62 | 1.03 |
Price to Tangible BV |
— | 4.08 | 4.85 | 12.83 | 4.60 | 10.01 | 25.88 | 33.21 | 3.78 | 1.03 |
EV/Sales |
— | 3.27 | 3.41 | 21.50 | 8.68 | 3.98 | 4.36 | 4.80 | 5.52 | 1.47 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 40.31 | 0.00 | 0.00 | 0.00 | 0.00 | 9.47 |
EV/Operating CF |
— | (3.75) | (0.63) | (17.81) | (34.13) | (87.81) | (25.30) | (6.60) | 76.67 | (19.01) |
EV/FCF |
— | (3.69) | (0.63) | (17.54) | (33.33) | (83.25) | (24.79) | (6.57) | 88.72 | (18.94) |
Quick Ratio |
2.35 | 2.50 | 0.79 | 2.16 | 8.32 | 1.28 | 0.81 | 0.57 | 1.22 | 3.93 |
Current Ratio |
2.43 | 2.97 | 1.29 | 2.69 | 9.62 | 1.83 | 1.20 | 0.83 | 1.88 | 4.87 |
Net Debt/EBITDA |
0.74 | 0.71 | 0.10 | 0.96 | (9.28) | 0.54 | (0.33) | (0.28) | 0.41 | (0.69) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 11.33% | 15.42% | 19.39% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.26 | 0.32 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.31 | 0.18 | 0.25 | 0.53 | 0.81 | 0.62 | 0.31 | 0.29 | 0.58 |
Operating CF/Net income |
1.32 | 0.57 | 0.94 | 0.57 | (2.11) | 0.10 | 0.46 | 0.48 | (0.11) | (4.97) |
Capex/Depreciation |
(0.01) | (0.59) | (2.47) | (3.50) | (1.78) | (0.23) | (0.23) | (0.11) | (0.28) | (0.02) |
Interest Coverage |
— | (59.54) | (38.64) | (19.11) | 2.66 | (3.19) | (1.37) | (7.07) | — | — |
| (89.74%) | (145.40%) | (181.80%) | (71.50%) | 8.11% | (60.77%) | (38.88%) | (61.43%) | (20.88%) | 1.03% | |
| (50.36%) | (68.45%) | (100.50%) | (53.61%) | 6.44% | (36.08%) | (23.54%) | (46.13%) | (18.31%) | 0.91% | |
ROIC |
(120,852.54%) | (339.52%) | (583.07%) | (2,001.85%) | 27.09% | (41.21%) | (11.72%) | (37.15%) | (11.75%) | 5.98% |
Return on Tangible Assets |
(197.71%) | (158.59%) | (1,374.91%) | (126.42%) | 5.41% | (150.58%) | (382.87%) | 1,217.74% | (160.32%) | 2.50% |
Average Days of Receivables |
— | 85.60 | 100.93 | 32.93 | 52.40 | 44.80 | 57.63 | 91.40 | 91.38 | 177.78 |
Research and Development Expense of Revenue |
0.00% | 75.70% | 314.18% | 180.18% | 53.37% | 39.76% | 43.21% | 68.40% | 22.53% | 0.45% |
Selling, General and Administrative Expense of Revenue |
0.00% | 145.74% | 294.89% | 109.71% | 33.74% | 34.04% | 45.12% | 93.34% | 84.23% | 39.54% |
Intangible Assets out of Total Assets |
0.23 | 0.11 | 0.14 | 0.08 | 0.06 | 0.25 | 0.50 | 0.56 | 0.50 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 80.80% | 109.95% | 28.57% | 8.24% | 6.21% | 5.99% | 10.33% | 5.54% | 2.26% |
Graham Net Nets |
— | 0.07 | (0.12) | 0.06 | 0.19 | 0.03 | (0.03) | (0.11) | 0.04 | 0.33 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 24.17 | 0.00 | 0.00 | 0.00 | 0.00 | 5.47 |
Earnings Yield |
— | (36.36%) | (183.82%) | (9.11%) | 1.52% | (10.69%) | (8.33%) | (33.59%) | (10.13%) | 0.92% |
Free Cash Flow Yield |
— | (21.23%) | (142.96%) | (5.23%) | (2.45%) | (1.16%) | (4.09%) | (16.44%) | 1.08% | (4.92%) |
Revenue per Share |
0.00 | 1.25 | 1.92 | 4.91 | 8.03 | 6.38 | 5.02 | 2.95 | 3.94 | 7.72 |
Operating CF per Share |
(2.05) | (1.61) | (10.36) | (5.93) | (2.04) | (0.29) | (0.87) | (2.14) | 0.28 | (0.60) |
Capex per Share |
0.00 | (0.01) | (0.08) | (0.09) | (0.05) | (0.02) | (0.02) | (0.01) | (0.04) | 0.00 |
Free Cash Flow per Share |
(2.05) | (1.62) | (10.44) | (6.02) | (2.09) | (0.30) | (0.88) | (2.15) | 0.25 | (0.60) |
Cash per Share |
1.25 | 1.90 | 1.13 | 10.01 | 16.04 | 2.04 | 0.99 | 0.70 | 0.95 | 0.83 |
Shareholders Equity per Share |
1.25 | 2.40 | 2.32 | 10.33 | 19.97 | 4.51 | 5.11 | 5.47 | 13.99 | 11.84 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.25 | 2.40 | 2.32 | 10.33 | 19.97 | 4.51 | 5.11 | 5.47 | 13.99 | 11.84 |
Free Cash Flow |
(30.04) | (21.84) | (88.68) | (48.24) | (15.95) | (2.04) | (5.59) | (11.60) | 0.85 | (1.72) |
Working Capital |
11.13 | 23.36 | 5.12 | 65.29 | 135.99 | 12.29 | 2.79 | (2.37) | 4.81 | 12.94 |
Capital Expenditures |
0.00 | (0.16) | (0.67) | (0.73) | (0.38) | (0.11) | (0.11) | (0.05) | (0.13) | (0.01) |
Net Current Asset Value |
7.41 | 7.12 | (7.41) | 51.44 | 125.90 | 5.58 | (4.49) | (7.79) | 3.41 | 11.60 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 40.97 | 0.00 | 0.00 | 0.00 | 0.00 | 10.80 |
Capex to Sales |
0.00 | 0.01 | 0.04 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 50.15 | 0.00 | 0.00 | 0.00 | 0.00 | 11.59 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.42 | 0.56 | 0.16 | 0.18 | 0.36 | 1.48 | 1.34 | 1.12 | 0.87 | 0.51 |
Cash ROIC |
(81.97%) | (37.67%) | (302.62%) | (29.60%) | (5.81%) | (4.11%) | (11.93%) | (27.20%) | 1.64% | (4.74%) |
Accounts Receivable Turnover |
— | 3.99 | 4.05 | 6.38 | 8.74 | 8.31 | 7.07 | 4.29 | 1.92 | 1.78 |
Accounts Payable Turnover |
0.00 | 1.45 | 0.50 | 0.69 | 4.29 | 3.98 | 3.20 | 2.40 | 3.92 | 9.87 |
Inventory Turnover |
— | 2.04 | 1.14 | 1.23 | 2.17 | 2.28 | 3.41 | 2.80 | 2.52 | 4.14 |
Average Days of Payables |
0.00 | 74.76 | 540.59 | 916.49 | 93.35 | 86.96 | 112.41 | 166.03 | 147.72 | 29.15 |
Days of Inventory on Hand |
— | 137.11 | 279.97 | 359.00 | 152.61 | 207.28 | 131.21 | 118.48 | 152.24 | 103.65 |
Average Receivables |
— | 4.23 | 4.03 | 6.17 | 7.01 | 5.12 | 4.50 | 3.70 | 7.10 | 12.44 |
Average Payables |
2.69 | 7.60 | 17.47 | 12.71 | 3.11 | 2.97 | 3.18 | 2.96 | 1.69 | 0.89 |
Average Inventory |
— | 5.42 | 7.66 | 7.10 | 6.14 | 5.18 | 2.97 | 2.53 | 2.63 | 2.12 |
Average Assets |
45.13 | 55.22 | 92.69 | 156.75 | 114.85 | 52.59 | 51.04 | 51.89 | 46.98 | 38.05 |
Average Common Equity |
25.32 | 26.00 | 51.24 | 117.55 | 91.20 | 31.22 | 30.91 | 38.97 | 41.19 | 33.53 |
Columns are period end dates